Evans syndrome
MONDO:0016030Evans syndrome is a rare chronic hematologic disorder characterized by the simultaneous or sequential association of autoimmune hemolytic anemia (AIHA; a disorder in which auto-antibodies are directed against red blood cells causing anemia of varying degrees of severity) with immune thrombocytopenic purpura (ITP; a coagulation disorder in which auto-antibodies are directed against platelets causing hemorrhagic episodes) and occasionally autoimmune neutropenia, in the absence of a known underlying etiology.
Also known as: Evans' syndrome, autoimmune hemolytic anaemia and autoimmune thrombocytopenia, autoimmune hemolytic anemia and autoimmune thrombocytopenia, immune pancytopenia, Evan syndrome
60 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
Cheap drug combo may tame tough anemia
Disease control TerminatedThis trial tests a combination of two drugs, sirolimus and all-trans retinoic acid (ATRA), for people with autoimmune anemia that has not responded to standard treatments. Autoimmune anemia occurs when the immune system attacks red blood cells, causing fatigue and other symptoms.…
Phase: PHASE4 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Could a week of antibiotics stop joint infections after replacement surgery?
Disease control ENROLLING_BY_INVITATIONThis study tests whether taking a 7-day course of oral antibiotics after hip or knee replacement surgery can prevent joint infections in patients at higher risk due to conditions like obesity, diabetes, or autoimmune disease. About 4,600 participants will receive one of three ant…
Phase: PHASE4 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Experimental CAR-T therapy targets tough autoimmune conditions
Disease control TerminatedThis early-phase study tests a new type of CAR-T cell therapy in 9 people with autoimmune diseases that have not responded well to standard treatments. The therapy uses specially engineered immune cells to target and attack faulty immune cells. The main goal is to check safety an…
Phase: EARLY_PHASE1 • Sponsor: Beijing Boren Hospital • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Fetal stem cells aim to tame immune chaos
Disease control ENROLLING_BY_INVITATIONThis early-stage trial tests clonal fetal mesenchymal stem cells (cfMSCs) in 100 people with severe immune-related disorders or tissue damage. The goal is to see if the cells are safe and can reduce symptoms. Participants have no other treatment options left.
Phase: PHASE1 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Could a cancer drug fix blood cell problems after transplant?
Disease control OngoingThis phase 2 trial tests whether isatuximab can help people whose blood cell counts stay low after a stem cell transplant for blood cancer. The study enrolls 12 adults whose disease is in remission but who have developed immune-related blood cell deficiencies. Participants receiv…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New blood treatment could block zika in transfusions
Disease control OngoingThis study tests a special treatment for red blood cells that aims to kill the Zika virus, making transfusions safer. About 692 people who need blood transfusions will receive either treated or standard blood. The goal is to see if the treated blood works just as well and is safe…
Phase: PHASE3 • Sponsor: Cerus Corporation • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Study withdrawn: extended access to fostamatinib for transplant patients never launched
Disease control TerminatedThis study was designed to give people who had a stem cell transplant and developed low blood cell counts (anemia, low platelets) continued access to the drug fostamatinib. Only those who responded well in a prior study were eligible. The goal was to see if they could maintain st…
Phase: PHASE2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New tool could predict who will suffer from steroid side effects
Knowledge-focused OngoingThis study aims to create a tool that predicts which patients with inflammatory rheumatic diseases (like rheumatoid arthritis, vasculitis, or polymyalgia rheumatica) will develop serious side effects from long-term steroid use. Researchers will collect routine medical data—such a…
Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
New registry aims to unlock safer pregnancies for women with autoimmune conditions
Knowledge-focused ENROLLING_BY_INVITATIONThis registry enrolls up to 1,000 women aged 12–55 with rheumatic or autoimmune diseases who are pregnant or planning pregnancy. Researchers will collect data from medical records and patient surveys to study pregnancy outcomes, disease activity, and medication use. No experiment…
Sponsor: Duke University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Immune cell showdown: autoimmune vs. infection vs. healthy
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at immune cells from people with autoimmune diseases (like lupus), people with infections, and healthy volunteers. Researchers want to understand how these cells differ and what makes them attack the body in autoimmune conditions. The study involves blood and bon…
Sponsor: Emory University • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC